Experienced in Frontotemporal Dementia

Chiung-chih M. Chang

No. 123 Ta Pei Rd, Niau Sung Dist, 833401, 
Kaohsiung, KHQ, TW 
Experienced in Frontotemporal Dementia
No. 123 Ta Pei Rd, Niau Sung Dist, 833401, 
Kaohsiung, KHQ, TW 
OverviewLocationsClinical Research

Overview

Chiung-chih Chang practices in Kaohsiung, Taiwan. Chang is rated as an Experienced expert by MediFind in the treatment of Frontotemporal Dementia. Their top areas of expertise are Alzheimer's Disease, Dementia, Meningitis, and Developmental Dysphasia Familial.

Their clinical research consists of co-authoring 141 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Frontotemporal Dementia.

Locations

No. 123 Ta Pei Rd, Niau Sung Dist, 833401, Kaohsiung, KHQ 83340, Taiwan
Other Locations
Ministry Of Economic Affairs, TPQ, Taiwan
Taoyuan, TNQ 33302, Taiwan
Taipei, TNQ, Taiwan
Tainan, TNQ, Taiwan
Taitung, TNQ, Taiwan
Jiayi Shi, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311)
An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311)
Enrollment Status: Terminated
Publish Date: January 26, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311) in Patients With Mild Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311) in Patients With Mild Alzheimer's Disease
Enrollment Status: Completed
Publish Date: March 17, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 1 Less Clinical Trial

141 Total Publications

Disentangling Tau, Glymphatic Dysfunction and Astrocytic Activation in Amyloid-Positive Alzheimer's Disease.
Disentangling Tau, Glymphatic Dysfunction and Astrocytic Activation in Amyloid-Positive Alzheimer's Disease.
Journal: Mechanisms of ageing and development
Published: June 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chang's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile